Irritable Bowel Syndrome
Conditions
Keywords
Irritable Bowel Syndrome, Sacral Nerve Stimulation, Gastro-colic response, Multimodal Stimulation
Brief summary
Sacral nerve stimulation (SNS) has become a well-established treatment for patients with fecal incontinence since 1995. The mechanism of action of SNS is still not fully understood but recent studies have shown changes in both colonic motility and rectal sensibility. The investigators have previously shown IBS patients to benefit from sacral nerves stimulation. With the present study, the investigators aim to evaluate if sacral nerve stimulation alters the gastro-colic response in IBS patients.
Detailed description
Twenty four patients with IBS-D or IBS-M according to the ROME III criteria, will be enrolled in the study. Having meet inclusion criteria, the patients will be examined with Multimodal Stimulation at baseline and at six weeks in the sacral nerve stimulation test period. During the Multimodal Stimulation the patients will have impedance planimetry conducted before and after a standardised meal to evaluate on their gastro-colic response without and during sacral nerve stimulation. The patients enrolled in the study will in the same time period participate in another study evaluating subsensory sacral nerve stimulation. A study registered at clinical trials. Here patients are randomised to receive either OFF-subsensory or subsensory-OFF stimulation in a 2+2-week period followed by 2 weeks of suprasensory stimulation. Hereby rendering a stimulation test period of a total of 6 weeks (a permanent electrode is used).
Interventions
DEVICEsacral nerve stimulation
Sacral nerve stimulation
Sponsors
Medtronic
University of Aarhus
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Patients aged over 18 * Patients who are psychologically stable and suitable for intervention and able to provide informed consent. * Patients who are diagnosed with IBS-D or IBS-M according to the Rome III criteria * Minimum average of 40 points in the symptom questionnaire evaluated at baseline
Exclusion criteria
* Overt bowel diseases including inflammatory bowel disease * Pregnant or breast feeding * Patients who are considered unable to follow the planned programme of the study, including mentally illness or physiological instability * Patients who are on medication with known influence on gastrointestinal motility including those for thyroid disease, diabetes mellitus, celiac disease and neurological disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cross sectional area | Change from baseline in cross sectional area at 6 weeks of stimulation | Patients will be examined with Multimodal Stimulation using impedance planimetry measuring the cross sectional area before and after a standardised meal at baseline and at 6 weeks of stimulation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Compliance | Change from baseline in compliance at 6 weeks of stimulation | Patients will be examined with Multimodal Stimulation using impedance planimetry measuring the compliance before and after a standardised meal at baseline and at 6 weeks of stimulation |
| Wall stiffness | Change from baseline in wall stiffness at 6 weeks of stimulation | Patients will be examined with Multimodal Stimulation using impedance planimetry calculating the wall stiffness before and after a standardised meal at baseline and at 6 weeks of stimulation |
| Cold | Change from baseline in cold tolerance at 6 weeks of stimulation | Patients will be examined with Multimodal Stimulation using impedance planimetry measuring the cold tolerance before and after a standardised meal at baseline and at 6 weeks of stimulation |
| Heat | Change from baseline in heat tolerance at 6 weeks of stimulation | Patients will be examined with Multimodal Stimulation using impedance planimetry measuring the heat tolerance before and after a standardised meal at baseline and at 6 weeks of stimulation |
Countries
Denmark
Outcome results
None listed